Abstract
Laboratory models show antineoplastic activity of metformin under certain conditions, and pharmacoepidemiologic studies have reported reduced cancer burden among diabetics taking metformin. Therefore, the hypothesis that metformin has antineoplastic activity is receiving increasing attention. However, gaps in knowledge must be addressed before metformin can be "repurposed" for oncologic indications.
©2012 AACR.
Publication types
- Research Support, Non-U.S. Gov't
MeSH terms
- Antineoplastic Agents / pharmacology
- Antineoplastic Agents / therapeutic use*
- Diabetes Complications / drug therapy
- Diabetes Mellitus / drug therapy*
- Humans
- Hypoglycemic Agents / pharmacology
- Hypoglycemic Agents / therapeutic use
- Metformin / pharmacology
- Metformin / therapeutic use*
- Pancreatic Neoplasms / complications
- Pancreatic Neoplasms / drug therapy*
- Retrospective Studies
Substances
- Antineoplastic Agents
- Hypoglycemic Agents
- Metformin